KR101995753B1 - 공통 경쇄를 가진 항체를 발현하는 비-사람 동물 - Google Patents

공통 경쇄를 가진 항체를 발현하는 비-사람 동물 Download PDF

Info

Publication number
KR101995753B1
KR101995753B1 KR1020137030963A KR20137030963A KR101995753B1 KR 101995753 B1 KR101995753 B1 KR 101995753B1 KR 1020137030963 A KR1020137030963 A KR 1020137030963A KR 20137030963 A KR20137030963 A KR 20137030963A KR 101995753 B1 KR101995753 B1 KR 101995753B1
Authority
KR
South Korea
Prior art keywords
human
mouse
light chain
sequence
rearranged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137030963A
Other languages
English (en)
Korean (ko)
Other versions
KR20140024909A (ko
Inventor
존 맥훠터
린 맥도날드
션 스티븐스
사무엘 데이비스
데이비드 알. 버클러
캐롤리나 에이. 호시아와
앤드류 제이 머피
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101995753(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20140024909A publication Critical patent/KR20140024909A/ko
Application granted granted Critical
Publication of KR101995753B1 publication Critical patent/KR101995753B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020137030963A 2011-04-25 2012-04-24 공통 경쇄를 가진 항체를 발현하는 비-사람 동물 Active KR101995753B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/093,156 2011-04-25
US13/093,156 US20120021409A1 (en) 2010-02-08 2011-04-25 Common Light Chain Mouse
PCT/US2012/034737 WO2012148873A2 (en) 2011-04-25 2012-04-24 Non-human animals expressing antibodies having a common light chain

Publications (2)

Publication Number Publication Date
KR20140024909A KR20140024909A (ko) 2014-03-03
KR101995753B1 true KR101995753B1 (ko) 2019-07-03

Family

ID=46000410

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137030963A Active KR101995753B1 (ko) 2011-04-25 2012-04-24 공통 경쇄를 가진 항체를 발현하는 비-사람 동물

Country Status (24)

Country Link
US (2) US20120021409A1 (enExample)
EP (2) EP2989893B1 (enExample)
JP (2) JP6393613B2 (enExample)
KR (1) KR101995753B1 (enExample)
CN (2) CN105884887A (enExample)
AU (3) AU2012249953B2 (enExample)
BR (1) BR112013027420A2 (enExample)
CA (1) CA2846806A1 (enExample)
CY (2) CY1117606T1 (enExample)
DK (2) DK2989893T3 (enExample)
ES (2) ES2573828T5 (enExample)
HR (2) HRP20160484T4 (enExample)
HU (2) HUE045401T2 (enExample)
IL (1) IL228929A0 (enExample)
LT (1) LT2989893T (enExample)
MX (1) MX353609B (enExample)
PL (2) PL2701499T5 (enExample)
PT (1) PT2989893T (enExample)
RS (2) RS54831B2 (enExample)
RU (2) RU2017108634A (enExample)
SG (1) SG194466A1 (enExample)
SI (2) SI2989893T1 (enExample)
SM (2) SMT201900514T1 (enExample)
WO (1) WO2012148873A2 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
CA2789154C (en) * 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
PL4067496T3 (pl) 2011-02-25 2023-07-31 Regeneron Pharmaceuticals, Inc. Myszy adam6
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
RS66089B1 (sr) 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP3839049A3 (en) 2011-09-19 2021-10-20 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
RU2743589C2 (ru) 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
RU2018128915A (ru) 2012-03-16 2019-02-18 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К рН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
JP2015519076A (ja) * 2012-06-12 2015-07-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
CN105734081A (zh) * 2013-02-20 2016-07-06 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
KR20150126863A (ko) * 2013-03-13 2015-11-13 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄 마우스
EP2967013B1 (en) * 2013-03-13 2019-01-16 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
PL3046412T3 (pl) 2013-09-18 2019-11-29 Regeneron Pharma Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10894818B2 (en) 2014-10-03 2021-01-19 Massachusetts Institute Of Technology Antibodies that bind Ebola glycoprotein and uses thereof
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
MX389267B (es) 2014-12-23 2025-03-20 Bristol Myers Squibb Co Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit).
JP2018508224A (ja) * 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
MX2018002493A (es) * 2015-08-27 2018-06-07 Crystal Bioscience Inc Animal transgenico para la produccion de anticuerpos que tienen una cadena ligera comun.
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3377532B1 (en) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN114128676A (zh) 2016-01-13 2022-03-04 瑞泽恩制药公司 具有包括改造的多样性簇的免疫球蛋白重链可变区的非人动物及其用途
JP2019514844A (ja) 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
SG11201807677YA (en) 2016-03-04 2018-10-30 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
WO2017159287A1 (ja) 2016-03-14 2017-09-21 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
CN109476742B (zh) 2016-05-09 2023-04-14 百时美施贵宝公司 Tl1a抗体及其用途
CN109475109B (zh) 2016-05-20 2021-10-29 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
PT4218408T (pt) 2016-06-03 2025-03-26 Regeneron Pharma Roedores que expressam desoxinucleotidil-transferase terminal exógena
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
CR20190193A (es) 2016-10-13 2019-08-21 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
SI3773713T1 (sl) 2018-04-06 2025-08-29 Regeneron Pharmaceuticals, Inc. Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
NZ777032A (en) 2018-11-16 2024-07-26 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
AU2020226865A1 (en) 2019-02-22 2021-07-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
TW202120556A (zh) 2019-08-08 2021-06-01 美商再生元醫藥公司 新穎抗原結合分子型式
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
WO2022140494A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
EP4051700B1 (en) 2020-12-23 2025-05-07 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
TW202430641A (zh) * 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20060015957A1 (en) 1991-08-28 2006-01-19 Genpharm International, Inc. Transgenic non-human animals for producing chimeric antibodies
WO2009157771A2 (en) 2008-06-27 2009-12-30 Merus B.V. Antibody producing non-human mammals
US20100310586A1 (en) 2007-07-27 2010-12-09 ARETA INTERNATIONAL S.r.l Idiotypic vaccine
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
DE69133476T2 (de) * 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
WO1998046645A2 (en) * 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2298809A3 (en) * 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
ATE476504T1 (de) * 2001-10-01 2010-08-15 Deutsches Krebsforsch Verfahren zur herstellung von protein- bibliotheken und zur selektion von proteinen daraus
EP1461442B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
US20050095712A1 (en) * 2002-01-17 2005-05-05 Alberto Martin Mutations caused by activation-induced cytidine deaminase
AU2003277087B2 (en) * 2002-06-14 2008-07-31 Immunomedics, Inc. Humanized monoclonal antiboby hPAM4
PT2314629E (pt) * 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
DK2767161T3 (en) 2004-10-19 2018-05-07 Regeneron Pharma Method of generating an animal homozygous for genetic modification
WO2007065433A2 (en) * 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101688228B (zh) * 2007-03-13 2014-12-24 国家犾太健康中心 抗体产生的方法
JP2012508017A (ja) * 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
CN102449149B (zh) * 2009-05-29 2014-04-23 莫佛塞斯公司 集合及其使用方法
KR102010827B1 (ko) * 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
SG10201609535TA (en) 2012-06-05 2017-01-27 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060015957A1 (en) 1991-08-28 2006-01-19 Genpharm International, Inc. Transgenic non-human animals for producing chimeric antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2004524841A (ja) * 2001-02-16 2004-08-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 真核生物細胞を改変する方法
US20100310586A1 (en) 2007-07-27 2010-12-09 ARETA INTERNATIONAL S.r.l Idiotypic vaccine
WO2009157771A2 (en) 2008-06-27 2009-12-30 Merus B.V. Antibody producing non-human mammals
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse

Also Published As

Publication number Publication date
HUE045401T2 (hu) 2019-12-30
WO2012148873A4 (en) 2013-03-14
US20120021409A1 (en) 2012-01-26
NZ617158A (en) 2016-04-29
SMT201600133B (it) 2016-07-01
AU2016202609A1 (en) 2016-05-19
US20150313193A1 (en) 2015-11-05
HRP20160484T4 (hr) 2021-12-10
SI2701499T1 (sl) 2016-10-28
SI2989893T1 (sl) 2019-10-30
AU2016202609B2 (en) 2018-07-12
EP2701499B9 (en) 2016-05-18
HRP20191680T1 (hr) 2019-12-13
WO2012148873A2 (en) 2012-11-01
SMT201900514T1 (it) 2019-11-13
MX353609B (es) 2018-01-18
HK1193718A1 (zh) 2014-10-03
EP2701499B2 (en) 2021-08-18
IL228929A0 (en) 2013-12-31
EP2989893A1 (en) 2016-03-02
ES2573828T5 (es) 2022-02-28
AU2012249953B2 (en) 2016-01-28
CN105884887A (zh) 2016-08-24
HK1220866A1 (en) 2017-05-19
JP2014516518A (ja) 2014-07-17
JP6393613B2 (ja) 2018-09-19
PL2989893T3 (pl) 2019-12-31
EP2989893B1 (en) 2019-06-19
CA2846806A1 (en) 2012-11-01
LT2989893T (lt) 2019-09-10
SI2701499T2 (sl) 2022-01-31
RU2013152221A (ru) 2015-05-27
JP2016178948A (ja) 2016-10-13
AU2012249953A1 (en) 2013-05-02
EP2701499B1 (en) 2016-02-10
HUE027949T2 (en) 2016-11-28
PT2989893T (pt) 2019-09-23
PL2701499T5 (pl) 2021-12-13
ES2573828T3 (es) 2016-06-10
DK2701499T4 (da) 2021-11-15
ES2743681T3 (es) 2020-02-20
AU2018236913A1 (en) 2018-10-25
JP6522557B2 (ja) 2019-05-29
HRP20160484T1 (hr) 2016-06-03
CN103596424A (zh) 2014-02-19
EP2701499B8 (en) 2016-03-16
CY1122036T1 (el) 2020-10-14
DK2989893T3 (da) 2019-09-09
CY1117606T1 (el) 2017-04-26
SG194466A1 (en) 2013-12-30
AU2016202609A2 (en) 2017-02-02
RS54831B2 (sr) 2021-12-31
RS54831B1 (sr) 2016-10-31
KR20140024909A (ko) 2014-03-03
WO2012148873A3 (en) 2013-02-07
EP2701499A2 (en) 2014-03-05
BR112013027420A2 (pt) 2016-08-09
RU2017108634A (ru) 2019-01-22
RS59331B1 (sr) 2019-10-31
DK2701499T3 (en) 2016-05-23
CN103596424B (zh) 2016-01-20
PL2701499T3 (pl) 2017-03-31
RU2614859C2 (ru) 2017-03-29
MX2013012500A (es) 2014-02-03

Similar Documents

Publication Publication Date Title
JP7538907B2 (ja) 共通の軽鎖のマウス
KR101995753B1 (ko) 공통 경쇄를 가진 항체를 발현하는 비-사람 동물
AU2020203238B2 (en) Mice expressing a limited immunoglobulin light chain repertoire
CN104582476B (zh) 使用共同轻链制备完全人双特异性抗体的方法
AU2016202488C1 (en) Common light chain mouse
US20130045492A1 (en) Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR20150126863A (ko) 공통 경쇄 마우스
AU2016203148B2 (en) Common light chain mouse
RU2812814C2 (ru) Мыши, экспрессирующие ограниченный репертуар легких цепей иммуноглобулина

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131121

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170418

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180918

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190426

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190627

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190628

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220520

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240527

Start annual number: 6

End annual number: 6